An interventional study of Energy restricted diet and Low carbohydrate high fat diet in Diabetes Mellitus, Type 2, Overweight and Obesity and Hypertension, sponsored by University of Bergen. Active, not recruiting at 1 site in Norway. Open to participants aged 24 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by University of Bergen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway — 3 open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Norway.
Among the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, this one is the 43rd largest by planned enrollment of the 103 interventional ones that give a count, is one of 2 that started in 2022, is one of 24 with no phase, and was the 111th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 18+
Boehringer Ingelheim · Sites in Norway, United States, Argentina and 48 more countries
Ages 18+
Apokus AS · Sites in Norway
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 24 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 56 · Phase 4 11
First in 1996; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 503 across the 103 interventional studies, 2,446 across the 13 observational. Of the 106 that completed or were terminated, 49 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 116 have an industry lead sponsor. The 10 most frequent:
University of Bergen is the lead sponsor of 143 studies on the registry; 19 are open to participants now.
University of Bergen has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus, Type 2 with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06273657Apokus ASEffects of Medisinstart for Type 2 Diabetes | 2027-02 |
| NCT07361640Oslo University HospitalDiaMester Pilot RCT: E-health Lifestyle Program for Type 2 Diabetes | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this project, the investigators will perform a multicenter randomised controlled trial to determine whether advice to consume a moderate, whole food-based low-carbohydrate high-fat (LCHF) ad libitum diet (CarbCount program) can produce and maintain equal remission rates of type 2 diabetes (T2D) as a nutritionally complete very-low-calorie formula diet followed by a energy-restrictive (i.e., calorie counting) diet (DiRECT principles). Within the principles of each approach, the dietary goals and change will be adjusted according to individual needs/capabilities conducive to long-term adherence. Furthermore, the investigators aim to determine whether the rate of diet-induced remission is reflected in/can be predicted by baseline or diet-induced changes in glucose variability (e.g., time-in-range measured by continuous glucose monitoring) and other factors such as anthropometric changes and genetic susceptibility. Each center will also conduct locally-lead standalone mechanistic research, including analyses of intra-abdominal/hepatic fat accumulation, adipose tissue biopsies and/or measurements of energy metabolism. Additionally, changes in medication use, nutritional status, cardiovascular disease risk, as well as adverse events, will be monitored.
At least 588 patients with T2D will be recruited, approximately 120-150 men and women at each research center. The participants will be randomised to 1) a nutritional complete formula diet for 3 months followed by an energy restricted diet for 12 months or 2) a very low-carbohydrate high-fat (VLCHF) diet for 3 months, followed by a low-carbohydrate high-fat diet (LCHF) for 12 months. Each of the diets will cover all basic requirements for essential nutrients including amino acids, fatty acids, vitamins and minerals. Participants will be encouraged to consume at least 200 g of vegetables per day. Furthermore, we will emphasize high-quality, minimally processed foods. In arm 2 they will receive advice to eat specific fat sources such as extra virgin olive oil, butter and high-fat cheeses.
The DiRECT trial showed remission in 46% of participants after 12 months. Assuming that both the DiRECT program and LCHF dietary strategies yield a 45% chance of T2D remission after 15 months, it is calculated (using nQuery v8) that each group needs 235 participants to complete the trial. This sample size yields 90% statistical power to conclude, with respect to the primary outcome, whether the CarbCount Program is no more than 15% more or less effective than the DiRECT principles (equivalence study, one-sided p-value at 0.025). To allow for expected loss to follow-up (estimated at 20%), each of the arms needs at least 294 participants for a total of 588.
Participants will have access to electronic platforms that include an online database of recipes (breakfast, easy-to-cook lunches, snacks, dinners, and food for special occasions). The platforms will facilitate planning of week menus, and include an e-learning course covering topics such as how to cook and prepare foods, meal planning, dining out, sleep and individual aspects that challenge habit change. If the participants are failing in their efforts to establish or maintain lifestyle change, they will be encouraged to seek possible solutions in the e-learning courses or to contact one of the study's health educators and/or dietitians. Specific rescue plans involving direct contact with study staff will be implemented if a participant regains more than 2 kg or experiences T2D relapse.
After individual assessment by a doctor, the participants will be taken off diabetes medication upon starting the diet, and be asked to self-monitor blood sugar changes during the first 2 weeks on the diet, followed by a consultation that includes evaluation of these changes. The need of reintroduction of medication will be done in consultation with the study doctor at least every 3 months.
Between visits, the participants will complete dietary assessments and an e-learning course, and at least once a month have follow-ups with dietitians/health educators and/or online group workshops.
The study will enroll eligible participants to the study continuously, until the total number of participants needed for the study is reached. Each participant will follow their own timeline, and attend visits at the study center at baseline, 3, 9 and 15 months.
During 2 weeks before each visit, participants will wear a continuous glucose monitor (CGM) and record food intake for at least 3 consecutive days during this period.
Measurements during visits will include anthropometric variables/body composition and energy expenditure, blood, saliva, urine and stool samples will be collected, and participants will be asked to fill out questionnaires on physical activity, sleep pattern, meal frequency, quality of life, problem areas in diabetes, eating efficacy and eating behaviors. They will also have a consultation with a registered dietitian and meet with the study medical doctor when needed.
A blinded statistician will perform the statistical analyses for the primary outcome of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A nutritional complete formula diet for 3 months followed by an energy restricted diet for 12 months.
Other: Energy restricted diet
A very low-carbohydrate high-fat ketogenic diet (VLCHF) diet for 3 months, followed by a low-carbohydrate high-fat diet (LCHF) for 12 months.
Other: Low carbohydrate high fat diet
Nutritional complete formula diet followed by an energy restricted diet
Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
Diabetes remission
Number of patients with diabetes remission, defined as no use of glucose-lowering drugs and HbA1c \<48 mmol/mol (\<6.5%) at 15 months
Time frame: 15 months
Diabetes remission without anti-diabetes medications
Number of patients with HbA1c \<48 and \<42 mmol/mol at 3, 9 and 15 months, both on and off anti-diabetes medication (metformin etc.)
Time frame: 3, 9 and 15 months
Changes in HbA1c and fasting glucose concentrations from baseline
HbA1c and fasting glucose concentrations (treatment targets in current clinical practice) measured in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in fasting insulin and insulin C-peptide concentrations from baseline
Insulin and insulin C-peptide measured in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in estimated insulin resistance and beta cell function from baseline
The HOMA2-calculator (https://www.dtu.ox.ac.uk/homacalculator/download.php) is used to estimate insulin resistance and beta cell function based on fasting glucose and C-peptide concentrations
Time frame: 3, 9 and 15 months
Changes from baseline in the frequency of diabetes- and antihypertensive medication usage
The number of diabetes- and antihypertensive medications used/reintroduced by each study visit counted and compared between groups
Time frame: 3, 9 and 15 months
Changes in eating behaviour from baseline and throughout the study
Eating behaviour measured by the The Weight Efficacy Lifestyle Questionnaire - Short form (WEL-SF). The questionnaire contains 8 items on a 10-point response scale (ranging from not at all confident/very confident). Responses to each item are given a score between 0-10, summed together and transformed to percentages. Changes in these scores will be compared between the study groups for the respective time-points throughout the intervention.
Time frame: 3, 9 and 15 months
Changes in eating self-efficacy (Three-Factor Eating Questionnaire, TFEQ)
Eating self-efficacy assessed by the Three-Factor Eating Questionnaire (TFEQ), which measures 3 aspects of eating behaviour: cognitive restraint, uncontrolled eating, and emotional eating. The questionnaire consists of 18 items on a 4-point response scale ( ranging from definitely true/mostly true/mostly false/definitely false). Responses to each item are given a score between 1 and 4 and and total scores are summed by the 3 measured aspects mentioned above. The raw scale scores are transformed to a 0-100 scale. Changes in these scores will be compared between the study groups for the respective time-points throughout the intervention.
Time frame: 3, 9 and 15 months
Changes in quality of life
Quality of life measured by the EQ-5D-5L questionnaire, which includes 5 dimensions: mobility, self-care, usual activities, pain /discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The levels are scored with a 1-digit number and the digits for the five dimensions are combined into a 5-digit number that describes the patient's health state. We will compare change at all timepoints between groups using both the 1-digit and the 5-digit number. The questionnaire includes the patient's self-rated health on a Visual analog scale (VAS) ranging from 0-100. The endpoints are labelled "The best health you can imagine" and "The worst health you can imagine". The scale will be transposed into percentages and the percent change will be compared between the study groups.
Time frame: 3, 9 and 15 months
Rates of T2D remission dependent on polygenic risk scores for T2D
Polygenic risk scores are calculated based on the latest GWAS data for T2D, and rates of remission compared between patients with the top 20% high- and top 20% low scores, for all participants combined and the respective diets separately
Time frame: 3, 9 and 15 months
Changes in ectopic fat accumulation from baseline
Body fat measured by MRI (abdominal adipose tissue distribution, hepatic-, intramuscular-, pericardial- and pancreatic fat)
Time frame: 3, 9 and 15 months
Changes in liver fibrosis and steatosis from baseline
Liver fibrosis and steatosis measured by ultrasound-based transient elastography
Time frame: 3, 9 and 15 months
Changes in markers of liver function from baseline
Alanine transaminase (ALT), C-reactive protein (CRP) and other markers of liver function measured in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in inflammatory markers from baseline
Circulating concentrations of selected markers of inflammation measured in fasting blood samples by ELISA
Time frame: 3, 9 and 15 months
Changes in blood pressure and pulse from baseline
Blood pressure and pulse measured after 10 minutes in resting position
Time frame: 3, 9 and 15 months
Change in CVD risk (NORRISK) from baseline
NORRISK calculated by the most current NORRISK calculator (https://hjerterisiko.helsedirektoratet.no/)
Time frame: 3, 9 and 15 months
Changes in total-, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and very-low-density (VLDL) cholesterol concentrations from baseline
Blood lipids measured in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in triacylglycerols (TGs) and TG/HDL-C ratio from baseline
Blood lipids measured in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in lipoprotein subfractions from baseline
Lipoprotein particle numbers and sizes (small/medium/large LDL, IDL, HDL, VLDL) measured in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in apolipoproteins from baseline
Apolipoproteins (including apoB, apoAs, ApoCs) measured in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in micronutrient status from baseline
Micronutrients measured in the circulation in fasting blood samples
Time frame: 3, 9 and 15 months
Changes in gut and oral microbiota from baseline
Gut and oral microbiota measured by 16S sequencing in feces and saliva, respectively
Time frame: 3, 9 and 15 months
Changes in appetite/satiety and ketones from baseline
Ghrelin and ketones measured in fasting blood samples, and correlations in the change of ghrelin and ketones (beta-hydroxybutyrate and acetoacetate) from baseline.
Time frame: 3, 9 and 15 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Sep 2026, 56 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 56 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2024 → Sep 2026 and completion Dec 2040 → Jun 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.